nach oben

CNS Drugs

Erschienen in:

01.01.2006 | Leading Article

Prion Diseases

Current Understanding of Epidemiology and Pathogenesis, and Therapeutic Advances

verfasst von: Dr Maria Caramelli, Giuseppe Ru, Pierluigi Acutis, Gianluigi Forloni

Erschienen in: CNS Drugs | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

The bovine spongiform encephalopathy (BSE) epidemic, along with the related threat to human health posed by the transmission of the BSE agent to humans, has highlighted the importance of prion diseases. These fatal neurodegenerative diseases are characterised by spongiform changes in the CNS, and comprise a wide spectrum of clinicopathological entities in humans and animals, such as Creutzfeldt-Jakob disease (CJD) and its emerging new variant (vCJD) in humans, and BSE and scrapie in animals. This article reviews the geographical distribution and the temporal trends of CJD and vCJD; the major events in the pathogenesis of prion diseases; the risk factors for sporadic CJD and vCJD; and the possible strategies for treating them.

Worldwide statistics indicate that sporadic CJD has a stable incidence of one case per million people per year; in contrast, the incidence of vCJD appears to have increased exponentially from its characterisation in 1994 to a peak in 2000. As of December 2005, 183 definite or probable cases of vCJD had been reported worldwide.

The crucial event in the pathogenesis of prion diseases is the conversion of the normally occurring cellular prion protein (PrP^c) into a pathogenic form, called protease-resistant PrP (PrP^res) or scrapie PrP (PrP^sc). Pathogenetic studies in rodent models have shown that PrP^sc is found in the enteric nervous system and in the gut-associated lymphoid tissue following oral scrapie ingestion. The role of the lymphoreticular system in the pathogenesis of TSE seems to be related to the strains of agents and the host genotype.

Therapeutic approaches to vCJD are mainly based on the inhibition or prevention of the pathological change that creates PrP^sc. Derivatives of acridine (such as mepacrine [quinacrine]) and the phenothiazine psychotropics have been proposed as possible therapies because of their activity in cellular models; however, neither class was able to affect the protease resistance of preexisting PrP fibrils. More encouragingly, in animal models of prion disease, tetracyclines were found to reduce prion infectivity by direct inactivation of PrP^sc. While these findings are promising, the suitability of these compounds for clinical use is still limited by their low efficacy once symptoms are apparent. Treatments based on the vaccination approach have also produced positive results, but further investigations are necessary to establish their clinical application.

Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004; 363: 51–61PubMedCrossRef

Chisea R, Piccardo P, Quaglio E, et al. Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol 2003; 77: 7611–22CrossRef

Prusiner SB. Prion diseases and the BSE crisis. Science 1997; 278: 245–51PubMedCrossRef

Wells GAH, Scott AC, Johnson CT, et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987; 121: 419–20PubMedCrossRef

Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921–5PubMedCrossRef

Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 1997; 389: 498–501PubMedCrossRef

Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448–50PubMedCrossRef

Collinge J, Sidle KC, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 1996; 383: 685–90PubMedCrossRef

Foster JD, Hope J, Fraser H. Transmission of bovine spongiform encephalopathy to sheep and goats. Vet Rec 1993; 133: 339–41PubMedCrossRef

10.

Forloni G. Immune system contributing to prion diseases. Drug Discov Today 2004; 1: 351–6CrossRef

11.

Anderson RM, Donnelly CA, Ferguson NM, et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996; 382: 779–87PubMedCrossRef

12.

Stevenson MA, Wilesmith JW, Ryan JB, et al. Temporal aspects of the epidemic of bovine spongiform encephalopathy in Great Britain: individual animal-associated risk factors for the disease. Vet Rec 2000; 147: 349–54PubMedCrossRef

13.

Beisel CE, Morens DM. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies. Clin Infect Dis 2004; 38: 697–704PubMedCrossRef

14.

Will RG. Epidemiology of Creutzfeldt-Jakob disease. Br Med Bull 1993; 49: 960–70PubMed

15.

Beghi E, Gandolfo C, Ferrarese C, et al. Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases. Neurol Sci 2004; 25(3): 122–9PubMedCrossRef

16.

Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A 1999; 96: 15137–42PubMedCrossRef

17.

Lasmezas CI, Deslys JP, Demaimay R, et al. BSE transmission to macaques. Nature 1996; 381: 743–4PubMedCrossRef

18.

Cousens SN, Zeidler M, Esmonde TF, et al. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970–96. BMJ 1997; 315: 389–95PubMedCrossRef

19.

National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK. Tenth annual report 2001 [online]. Available from URL: http://www.cjd.ed.ac.uk/rep2001.html [Accessed 2005 May 15]

20.

Coehn CH. Does improvement in case ascertainment explain the increase in sporadic Creutzfeldt-Jakob disease since 1970 in the United Kingdom? Am J Epidemiol 2000; 152: 474–9CrossRef

21.

Capek I, Vaillant V. Creutzfeldt-Jakob disease and related diseases in France from 1998 to 2000. Euro Surveill 2003; 8: 14–9PubMed

22.

Glatzel M, Rogivue C, Ghani A, et al. A Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet 2002; 360: 139–41PubMedCrossRef

23.

National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK: CJD statistics [online]. Available from URL: http://www.cjd.ed.ac.uk/eleventh/figures.htm [Accessed 2005 Dec 2]

24.

National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK. 2003. Eleventh annual report 2002 [online]. Available from URL: http://www.cjd.ed.ac.uk/eleventh/rep2002.htm [Accessed 2005 May 15]

25.

Cousens S, Smith PG, Ward H, et al. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994–2000. Lancet 2001; 357: 1002–7PubMedCrossRef

26.

Bryant G, Monk P. Final report of the investigation into the North Leicestershire cluster of variant Creutzfeldt-Jakob. 2001 [online]. Available from URL: http://www.leics-ha.org.uk [Accessed 2005 May 15]

27.

Alperovitch A, Zerr I, Pocchiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353: 1673–4PubMedCrossRef

28.

Jackson GS, Beck JA, Navarrete C, et al. HLA-DQ7 antigen and resistance to variant CJD. Nature 2001; 414: 269–70PubMedCrossRef

29.

Pepys MB, Bybee A, Booth DR, et al. MHC typing in variant Creutzfeldt-Jakob disease. Lancet 2003; 361: 487–9PubMedCrossRef

30.

Laplanche JL, Lepage V, Peoc’h K, et al. HLA in French patients with variant Creutzfeldt-Jakob disease. Lancet 2003; 361: 531–2PubMedCrossRef

31.

Aylin P, Bunting J, De Stavola B, et al. Mortality from dementia in occupations at risk of exposure to bovine spongiform encephalopathy: analysis of death registrations. BMJ 1999; 318: 1044–5PubMedCrossRef

32.

Collins S, Law MG, Fletcher A, et al. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999; 353: 693–7PubMedCrossRef

33.

Van Duijn CM, Delasnerie-Lauprêtre N, Fasullo C, et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993–1995. Lancet 1998; 351: 1081–5PubMedCrossRef

34.

Wientjens D, Davanipour Z, Hofman A, et al. Risk factors for Creutzfeldt-Jakob disease: a re-analysis of case-control studies. Neurology 1996; 46: 1287–91PubMedCrossRef

35.

Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999–1000PubMedCrossRef

36.

Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83: 2897–905PubMed

37.

Herzog C, Salès N, Etchegaray N, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet 2004; 363: 422–8PubMedCrossRef

38.

Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies. BMJ 2000; 321: 17–9PubMedCrossRef

39.

Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 120 heterozygous patient. Lancet 2004; 264: 527–9CrossRef

40.

Alperovitch A, Zerr I, Pochiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353: 1673–4PubMedCrossRef

41.

Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417–21PubMedCrossRef

42.

Andrews NJ, Farrington CP, Ward HJ, et al. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet 2003; 361: 751–2PubMedCrossRef

43.

Andrews NJ. Quarterly report. Incidence of variant Creutzfeldt-Jakob Disease onset and deaths in the UK (updated 23rd April 2004) [online]. Available from URL: http://www.cjd.ed.ac.uk/vcjdq.htm [Accessed 2005 May 15]

44.

Cousens SN, Vynnycky E, Zeidler M, et al. Predicting the CJD epidemic in humans. Nature 1997; 385: 197–8PubMedCrossRef

45.

Ghani AC, Ferguson NM, Donnelly CA, et al. Predicted vCJD mortality in Great Britain. Nature 2000; 406: 583–4PubMedCrossRef

46.

Ghani AC, Donnelly CA, Ferguson NM, et al. Updated projections of future vCJD deaths in the UK. BMC Infect Dis 2003; 3: 1–4CrossRef

47.

Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733–9PubMedCrossRef

48.

Kimberlin RH, Walker CA. Pathogenesis of mouse scrapie: dynamics of agent replication in spleen, spinal cord and brain after infection by different routes. J Comp Pathol 1979; 89: 551–62PubMedCrossRef

49.

Clarke MC, Haig DA. Multiplication of scrapie agent in mouse spleen. Res Vet Sci 1971; 12: 195–7PubMed

50.

Fraser H, Dickinson AG. Pathogenesis of scrapie in the mouse: the role of the spleen. Nature 1970; 226: 462–3PubMedCrossRef

51.

Fraser H, Dickinson AG. Studies of the lymphoreticular system in the pathogenesis of scrapie: the role of the spleen and thymus. J Comp Pathol 1978; 88: 563–73PubMedCrossRef

52.

Baldauf E, Beekes M, Diringer H. Evidence for an alternative direct route of access for the scrapie agent to the brain bypassing the spinal cord. J Gen Virol 1997; 78: 1187–97PubMed

53.

Beekes M, Baldauf E, Diringer H. Sequential appearance and accumulation of pathognomonic markers in the central nervous system of hamsters orally infected with scrapie. J Gen Virol 1996; 77: 1925–34PubMedCrossRef

54.

Kimberlin RH, Walker CA. Pathogenesis of scrapie in mice after intragastric infection. Virus Res 1989; 12: 213–20PubMedCrossRef

55.

Beekes M, McBride PA. Early accumulation of pathological PrP in the enteric nervous system and gut-associated lymphoid tissue of hamsters orally infected with scrapie. Neurosci Lett 2000; 278: 181–4PubMedCrossRef

56.

Maignien T, Lasmézas CI, Beringue V, et al. Pathogenesis of the oral route of infection of mice with scrapie and bovine spongiform encephalopathy agents. J Gen Virol 1999; 80: 3035–42PubMed

57.

Andréoletti O, Berthon P, Marc D, et al. Early accumulation of PrPsc in gut-associated lymphoid and nervous tissues of susceptible sheep from a Romanov flock with natural scrapie. J Gen Virol 2000; 81: 3115–26PubMed

58.

Van Keulen L, Schreuder EC, Vromans MEW, et al. Pathogenesis of natural scrapie in sheep. Arch Virol 2000; 16: 57–71

59.

McBride P, Schulz-Schaeffer WJ, Donaldson M, et al. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Gen Virol 2001; 75: 9320–7

60.

Kimberlin RH, Hall SM, Walker CA. Pathogenesis of mouse scrapie: evidence for direct neural spread of infection to the CNS after injection of sciatic nerve. J Neurol Sci 1983; 61: 315–25PubMedCrossRef

61.

Fraser H, Brown KL, Stewart K, et al. Replication of scrapie in spleen of SCID mice follows reconstitution with wild-type mouse bone-marrow. J Gen Virol 1996; 77: 1935–40PubMedCrossRef

62.

Kimberlin RH, Walker CA. Incubation period in six models of intraperitoneally injected scrapie depend mainly on the dynamics of agent replication within the nervous system and not the lymphoreticular system. J Gen Virol 1988; 69: 2953–60PubMedCrossRef

63.

Lasmezas CI, Cesbron JY, Deslys JP, et al. Immune system-dependent and independent replication of the scrapie agent. J Virol 1996; 70: 1292–5PubMed

64.

Schreuder BEC, Van Keulen L, Vromans MEW, et al. Tonsillar biopsy and PrPsc detection in the preclinical diagnosis of scrapie. Vet Rec 1998; 142: 564–8PubMedCrossRef

65.

Jeffrey M, Begara-McGorum I, Clark S, et al. Occurrence and distribution of infection-specific PrP in tissues of clinical scrapie cases and cull sheep from scrapie-affected farms in Shetland. J Comp Pathol 2002; 127: 264–73PubMedCrossRef

66.

Jeffrey M, Ryder S, Martin S, et al. Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE): 1. Onset and istribution of disease-specific PrP accumulation in brain and viscera. J Comp Pathol 2001; 124: 280–9

67.

Wells GAH, Hawkins SAC, Green RB, et al. Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy (BSE): an update. Vet Rec 1998; 142: 103–6PubMedCrossRef

68.

Wells GA, Spiropoulos J, Hawkins SA, et al. Pathogenesis of experimental bovine spongiform encephalopathy: preclinical infectivity in tonsil and observations on the distribution of lingual tonsil in slaughtered cattle. Vet Rec 2005; 156: 401–7PubMed

69.

Foster JD, Parnham DW, Hunter N, et al. Distribution of the prion protein in sheep terminally affected with BSE following experimental oral transmission. J Gen Virol 2001; 82: 2319–26PubMed

70.

Bruce ME, McConnell I, Will RG, et al. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001; 358: 208–9PubMedCrossRef

71.

Hill AF, Zeidler M, Ironside JW, et al. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99–100PubMedCrossRef

72.

Wadsworth JDF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358: 171–80PubMedCrossRef

73.

Hill AF, Butterworth RJ, Joiner S. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183–9PubMedCrossRef

74.

Jeffrey M, Martin S, Thomson JR, et al. Onset and distribution of tissue PrP: accumulation in scrapie-affected Suffolk sheep as demonstrated by sequential necropsies and tonsillar biopsies. J Comp Pathol 2001; 125: 48–57PubMedCrossRef

75.

Race R, Oldstone M, Chesebro B. Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol 2000; 74: 828–33PubMedCrossRef

76.

Brown P, Rohwer RG, Dunstan BC, et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810–6PubMedCrossRef

77.

Blattler T, Brandner S, Raeber AJ, et al. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 1997; 389: 69–73PubMedCrossRef

78.

Shlomchik MJ, Radebold K, Duclos N, et al. Neuroinvasion by a Creutzfeldt-Jakob disease agent in the absence of B cells and follicular dendritic cells. Proc Natl Acad Sci U S A 2001; 98: 9289–94PubMedCrossRef

79.

Klein MA, Frigg R, Flechsig E, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390: 687–90PubMed

80.

Klein MA, Frigg R, Raeber AJ, et al. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med 1998; 4: 1429–33PubMedCrossRef

81.

Jeffrey M, McGovern G, Goodsir GM, et al. Sites of prion protein accumulation in scrapie-infected mouse spleen revealed by immuno-electron microscopy. J Pathol 2000; 191: 323–32PubMedCrossRef

82.

Heggebo R, Press C, Gunnes G, et al. Distribution and accumulation of PrP in gut-associated and peripheral lymphoid tissue of scrapie-affected Suffolk sheep. J Gen Virol 2002; 83: 479–89PubMed

83.

Fraser H, Farquhar CF. Ionising radiation has no influence on scrapie incubation period in mice. Vet Microbiol 1987; 13: 211–23PubMedCrossRef

84.

O’Rourke KI, Huff TP, Leathers CW, et al. SCID mouse spleen does not support scrapie agent replication. J Gen Virol 1994; 75: 1511–4PubMedCrossRef

85.

Brown P, Stewart K, Ritchie DL, et al. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat Med 1999; 11: 1308–12CrossRef

86.

Montrasio F, Frigg R, Glatzel M, et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 2000; 288: 1257–9PubMedCrossRef

87.

Kaeser PS, Klein MA, Schwarz P, et al. Efficient lymphoreticular prion propagation requires PrPc in stromal and hematopoietic cells. J Virol 2001; 75: 7097–106PubMedCrossRef

88.

Manuelidis L, Zaitsev I, Koni P, et al. Follicular dendritic cells and dissemination of Creutzfeldt-Jakob disease. J Virol 2000; 74: 8614–22PubMedCrossRef

89.

Klein MA, Kaeser PS, Schwarz P, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7: 488–92PubMedCrossRef

90.

Mabbott NA, Bruce ME, Botto M, et al. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med 2001; 7: 485–7PubMedCrossRef

91.

Raeber AJ, Klein MA, Frigg R, et al. PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice. EMBO J 1999; 18: 2702–6PubMedCrossRef

92.

Bruce ME, Brown KL, Mabbott NA, et al. Follicular dendritic cells in TSE pathogenesis. Immunol Today 2000; 9: 442–6CrossRef

93.

Aucouturier P, Geissmann F, Damotte D, et al. Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J Clin Invest 2001; 108: 703–8PubMed

94.

Aguzzi A. Peripheral prion pursuit. J Clin Invest 2001; 108: 661–2PubMed

95.

Felten DL, Felten SY, Carlson SL, et al. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1989; 135: 755–65

96.

Heggebo R, Gonzalez L, Press C, et al. Disease-associated PrP in the enteric nervous system of scrapie-affected Suffolk sheep. J Gen Virol 2003; 84: 1327–38PubMedCrossRef

97.

Glatzel M, Aguzzi A. PrPc expression in the peripheral nervous system is a determinant of prion neuroinvasion. J Gen Virol 2000; 81: 2813–21PubMed

98.

McEwen BS, Grafstein B. Fast and slow components in axonal transport of protein. J Cell Biol 1968; 38: 494–508PubMedCrossRef

99.

Dormont D. Prion diseases: pathogenesis and public health concerns. FEBS Lett 2002; 529: 17–21PubMedCrossRef

100.

Brandner S, Raeber A, Saller A, et al. Normal host prion protein (PrPc) is required for scrapie spread within the central nervous system. Proc Natl Acad Sci U S A 1996; 93: 13148–51PubMedCrossRef

101.

Follett J, Lemaire-Vieille C, Blanquet-Grossard F, et al. PrP expression and replication by Schwann cells: implications in prion spreading. J Virol 2002; 76: 2434–9CrossRef

102.

Hegde RS, Tremblay P, Groth D, et al. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 1999; 402: 822–6PubMedCrossRef

103.

Chiesa R, Piccardo P, Quaglio E, et al. Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol 2003; 77: 7611–22PubMedCrossRef

104.

Soto C, Saborio G. Prions: disease propagation and disease therapy by conformational transmission. Trends Mol Med 2001; 7: 109–14PubMedCrossRef

105.

Forloni G, Vari M, Colombo L, et al. Prion diseases: time for a therapy? Curr Med Chem —Immun Endoc Metab Agents 2003; 3: 185–97CrossRef

106.

Ladogana A, Casaccia P, Ingrosso L, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992; 73: 661–5PubMedCrossRef

107.

Ehlers B, Diringer H. Dextran sulfate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984; 65: 1325–30PubMedCrossRef

108.

Adjou KT, Deslys JP, Demaimay R, et al. Probing the dynamics of prion diseases with amphotericin B. Trends Microbiol 1997; 5: 27–31PubMedCrossRef

109.

Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000; 287: 1503–6PubMedCrossRef

110.

Caughey WS, Raimond LD, Horiachi M, et al. Inhibition of protease-resistant prion protein formation by porphyrins and phtalocyamines. Proc Natl Acad Sci U S A 1998; 95: 12117–22PubMedCrossRef

111.

Supattapone S, Wille H, Uyechi L, et al. Branched polyamines cure prion infected neuroblastoma cells. J Virol 2001; 75: 3453–61PubMedCrossRef

112.

Korth C, May BC, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001; 98: 9836–41PubMedCrossRef

113.

Doh-ura K, Iwaki T, Caughey B. Lysomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000; 74: 4894–7PubMedCrossRef

114.

Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52: 503–6PubMedCrossRef

115.

Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003; 77: 8462–9PubMedCrossRef

116.

Brown P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 2002; 56: 1720–5CrossRef

117.

Follette P. Prion disease treatment’s early promise unravels. Science 2003; 299: 191–2PubMedCrossRef

118.

Furukawa H, Takahashi M, Nakajima M, et al. Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine. Nippon Rinsho 2002; 60: 1649–57PubMed

119.

Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995; 92: 2959–63PubMedCrossRef

120.

Gianni L, Belotti V, Gianni AM, et al. New drug therapy of myloidoses: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995; 86: 855–61PubMed

121.

Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997; 276: 1119–22PubMedCrossRef

122.

Mitscher LA. The chemistry of the tetracycline antibiotics. New York: Marcel Dekker, 1978

123.

Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000; 300: 1309–22PubMedCrossRef

124.

Forloni G, Jussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 2002; 99: 10849–53PubMedCrossRef

125.

Weiner HL, Selkoe D. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002; 420: 879–84PubMedCrossRef

126.

Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–7PubMedCrossRef

127.

Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003; 38: 547–54PubMedCrossRef

128.

Gabizon R, McKinley MP, Groth D, et al. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci U S A 1988; 85: 6617–21PubMedCrossRef

129.

Enari M, Flechsig E, Weissman C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by ‘exposure’ to ‘a ‘prion ‘protein antibody. Proc Natl Acad Sci U S A 2001; 98: 9295–9PubMedCrossRef

130.

Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibits prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739-43PubMedCrossRef

Titel: Prion Diseases
Current Understanding of Epidemiology and Pathogenesis, and Therapeutic Advances
verfasst von: Dr Maria Caramelli
Giuseppe Ru
Pierluigi Acutis
Gianluigi Forloni
Publikationsdatum: 01.01.2006
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 1/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620010-00002

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Prescription Privileges for Psychologists

Cataplexy Associated with Narcolepsy

Polytherapy in Bipolar Disorder

Inclusion of Patients with Severe Mental Illness in Clinical Trials